DefiniGEN has a unique platform technology for generating predictive, phenotypically relevant iPSC-derived human cell disease models for a wide range of metabolic and liver diseases, to support preclinical drug discovery. This is deployed through a unique set of compound profiling research services, driving drug development through the provision of vital pre-clinical human data.
Using finely optimised protocols first developed in the labs of Professor Ludovic Vallier at Cambridge University, DefiniGEN generate terminally differentiated human cells of unmatched quality from iPSC. Samples can be either derived from diseased patient material with associated clinical data, or a line may be gene edited with CRISPR to enable the generation of large-scale batches of diseased hepatocytes. A wide range of orphan disease indications can be modelled in vitro to characterise, de-risk and accelerate the passage of small molecules and gene therapies to the clinic.
Wednesday, 18th November, 2020
10:00am GMT (UTC+0)
hosted by Lilly Xu, Ph.D. Senior Vice President, DMPK & Exploratory Toxicology Dept, ChemPartner